ArticleNeuro-oncology advances
Enhancing efficiency in pediatric brain tumor segmentation using a pathologically diverse single-center clinical dataset.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Hierarchical Multimodal Fusion of Multi-Sequence MRI and Clinical Metadata for the Classification of Rotator Cuff Tears.Journal of clinical medicine · 2026Article
- Arterial spin labeling performs comparably to 2-[Epilepsia · 2026Article
- Enhancing efficiency in pediatric brain tumor segmentation using a pathologically diverse single-center clinical dataset.Neuro-oncology advancesArticle
- GlioMODA: Robust glioma segmentation in clinical routine.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain tumors are the most common solid malignancies in children, encompassing diverse histological, molecular subtypes, and imaging features and outcomes. Pediatric brain tumors (PBTs), including high- and low-grade gliomas (HGG and LGG), medulloblastomas (MB), ependymomas, and rarer forms, pose diagnostic and therapeutic challenges. Deep learning (DL)-based segmentation offers promising tools for tumor delineation, yet its performance across heterogeneous PBT subtypes and MRI protocols remains uncertain. Methods: A retrospective single-center cohort of 174 pediatric patients with HGG, LGG, MB, ependymomas, and other rarer subtypes was used. MRI sequences included T1, T1 post-contrast (T1-C), T2, and FLAIR. Manual annotations were provided for 4 tumor subregions: whole tumor (WT), T2-hyperintensity (T2H), enhancing tumor (ET), and cystic component (CC). A 3D nnU-Net model was trained and tested (121/53 split), with segmentation performance assessed using the Dice similarity coefficient (DSC) and compared against intra- and interrater variability. Results: The model achieved robust performance for WT and T2H (mean DSC: 0.85), comparable to human annotator variability (mean DSC: 0.86). ET segmentation was moderately accurate (mean DSC: 0.75), while CC performance was poor (mean DSC: 0.26). Segmentation accuracy varied by tumor type, MRI sequence combination, and location. Notably, T1, T1-C, and T2 combined produced results nearly equivalent to the full protocol. Conclusions: DL-based segmentation is feasible for PBTs, particularly for T2H and WT. Challenges remain for ET and CC segmentation, highlighting the need for further refinement. These findings support the potential for protocol simplification and automation to enhance volumetric assessment and streamline pediatric neuro-oncology workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.